Motherisk update: Toxoplasmosis during pregnancy

Canadian Family Physician

Volumn 52, Issue JAN., 2006, Pages 29-32

  Many, Ariel ^a   Koren, Gideon ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MACROLIDE; PYRIMETHAMINE; SPIRAMYCIN; SULFONAMIDE;

ANTIBODY TITER; ARTICLE; BRAIN CALCIFICATION; CANADA; CHORIORETINITIS; CLINICAL FEATURE; CONGENITAL TOXOPLASMOSIS; CORDOCENTESIS; CYST; FEMALE; FETUS; GASTROINTESTINAL SYMPTOM; HIGH RISK PREGNANCY; HUMAN; HYDROCEPHALUS; INFECTION CONTROL; LIFE CYCLE; NEWBORN; NEWBORN JAUNDICE; OOCYTE; PARASITE TRANSMISSION; PLANNING; PRACTICE GUIDELINE; PREGNANCY DISORDER; PRENATAL EXPOSURE; PROTOZOON; SCREENING TEST; THIRD TRIMESTER PREGNANCY; TOXOPLASMA GONDII; TOXOPLASMOSIS;

EID: 33744476406     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Bowie WR, King AS, Werker DH, Isaac-Renton JL, Bell A, Eng SB, et al. Outbreak of toxoplasmosis associated with municipal drinking water. The BC Toxoplasma Investigation Team. Lancet 1997;350:173-7.
2. Jones IL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB. Toxoplasma gondii infection in the United States: scroprevalence and risk factors. Am J Epidemiol 2001;154:357-65.
3. Shuhaber S, Koren G, Boskovic R, Einarson TR, Soldin OP, Einarson A. Seroprevalence of Toxoplasma, gondii infection among veterinarian staff in Ontario, Canada: implications for teratogenic risk. BMC Infect Dis 2003;3:8.
4. Guerina NG, Hsu HW, Meissner HC, Maguire JH, Lynfield R, Stechenberg B, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. Engl J Med 1994;330(26):1858-63.
5. Dunn D, Wallon M, Peyron F, Peterson E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counseling Lancet 1999;353:1829-33.
6. Foulon W, Naessens A, Lauwers S, De Meuter F. Amy JJ. Impact of primary prevention on the incidence of toxoplasmosis during pregnancy. Obstet Gynecol 1998;72(3 Pt 1):363-6.
7. Lopez A, Dietz VJ, Wilson M, Navin TR, Jones IL. Preventing congenital toxoplasmosis. MMWR Recomm Rep 2000;49(RR-2):59-68.
8. American College of Obstetricians and Gynecologists. Perinatal viral and parasitic infections. ACOG Pract Bull 2000, no, 20 (replaces educational bulletin number 177, February 1993). Int J Gynaecol Obstet 2002;76(1):95-107.
9. Wilson M, Remington JS, Clavet C, Varney G, Press C, Ware D. Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. The FDA Toxoplasmosis Ad Hoc Working Group. J Clin Microbiol 1997;35:3112-5.
10. Hohlfeld P, Daffos F, Costs JM, Thulliez P, Forestier F, Vidaud M. Prenatal diagnosis of congenital toxoplasmosis with PCR test on aminiotic. fluid. N Engl Med 1994;331:695-9.
11. Foulon W, Villena I, Stray-Pedersen B, Decoster A, Lappalainen M, Pinon JM, et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol 1999;180:410-5.
12. Gilbert R, Gras I; European Multicentre Study on Congenital Toxoplasmosis. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG, 2003;110:112-20.